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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic infl ammatory disease in which early aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) can improve outcomes and prevent joint damage. Treatment recommendations for the management of early arthritis concluded that the main goal of treatment is clinical remission, in order to prevent structural joint damage and long-term disability. 1 2 These recommendations acknowledge that patients with disease features of poor prognosis-for example, high disease activity and the presence of autoantibodies (rheumatoid factor (RF) and/or anticitrullinated peptide antibodies (ACPA))-should be considered as candidates for the early introduction of biological therapies.
Incorporating biological therapies into early treatment regimens has shown that remission of disease with inhibition of progressive joint destruction is an achievable treatment goal, although this has primarily been limited to biological agents that share a common mechanism of action-namely, inhibition of tumour necrosis factor (TNF). 3 -6 Rituximab is a therapeutic monoclonal antibody that selectively depletes CD20+B cells. The combination of rituximab with methotrexate (MTX) signifi cantly improves disease symptoms in patients with RA who have an inadequate response to conventional DMARD therapy, and ameliorates disease symptoms and protects against joint damage in patients who have had an inadequate response to TNF inhibitors. 7 -9 The aim of this study was to investigate the early therapeutic introduction of rituximab in patients with active RA not previously treated with MTX.
METHODS Patients
Patients were recruited between January 2006 and September 2007 from 169 centres in Europe, the USA, Latin America, Asia and Australia. Eligible patients were aged 18-80 years with RA diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria. 10 Disease duration was ≥8 weeks but ≤4 years. Patients were not to have received previous treatment with MTX and were to have active disease defi ned as a swollen joint count (66 joints) and tender joint count (68 joints) both ≥8 at screening and baseline, and C-reactive protein (CRP) ≥1.0 mg/dl. Patients seronegative for RF required radiographic evidence of erosive damage attributable to RA.
This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and adhered to the principles outlined in the Guideline for Good Clinical Practice ICH Tripartite Guideline (January 1997).
Procedures
Patients were randomised to receive rituximab (2×500 mg or 2×1000 mg) or placebo in addition to initiating MTX. The randomisation schedule, stratifi ed by region (USA or rest of world) and RF status (positive or negative), was generated by the sponsor and supplied to an Interactive Voice Response System (IVRS). At randomisation, patients were assigned unique medication and randomisation numbers via the IVRS. The sponsor, investigators and patients were blinded to treatment allocation until week 52, at which time the sponsor was unblinded for the purposes of data analysis. Rituximab/placebo was administered by intravenous infusion on days 1 and 15, with all ▶ Additional tables and fi gures are published online only. To view these fi les please visit the journal online (http://ard. bmj.com) non-parametric tests and the closure principle for multiplicity adjustment, a planned sample size of 250 patients per group was expected to give >90% power to detect differences between each rituximab group and MTX alone.
Radiographic analyses were performed on a modifi ed intent-to-treat (mITT) population, defi ned as randomised patients who received study medication and for whom a baseline and at least one post-baseline x-ray were available. Missing values at week 52 were imputed by linear extrapolation. For changes in radiographic scores, a global test was performed using the Kruskal-Wallis test to control for multiplicity, with primary comparisons made using a non-parametric test (Van Elteren) for the individual rituximab dose groups versus MTX alone, adjusting for baseline stratifi cation factors (region and RF status). The difference in the proportions of patients without radiographic progression was tested using the Cochran-Mantel-Haenszel (CMH) test, also adjusting for baseline stratifi cation factors; if progression status could not be determined, the patient was classed as 'progressed'. Radiographic non-progression was defi ned as a change in total modifi ed Sharp score ≤0.
Clinical effi cacy of rituximab versus placebo was analysed using the CMH test for categorical end points and analysis of variance (ANOVA) for continuous end points, adjusting for baseline stratifi cation factors. ANOVA models also included the end point baseline value if applicable (eg, for analysis of change in DAS28-ESR and HAQ-DI). Missing data were imputed using the non-responder method for ACR, EULAR and MCR (all patients who withdrew or received a non-permitted DMARD were classed as non-responders) and the last observation carried forward for all other end points.
RESULTS
Overall, 755 patients were randomised with 748 included in the ITT and safety analyses and 715 in the mITT analysis for radiographic outcomes. Baseline demographic and disease characteristics were balanced across treatment groups and indicated that this was an early MTX-naïve RA population with highly active disease (mean DAS28-ESR 7.0-7.1, mean tender joint count 32.7-34.0, mean swollen joint count 20.0-22.4) and a high degree of functional impairment ( table 1 ) . Approximately infusions ( including placebo) premedicated with intravenous methylprednisolone 100 mg. Oral MTX in all patients was commenced at 7.5 mg/week and escalated up to 20 mg/week by week 8 as tolerated.
Repeat courses of rituximab/placebo were permitted from week 24. Patients eligible for re-treatment were those with a Disease Activity Score in 28 joints (DAS28-ESR) ≥2. 6. 11 Patients with DAS28-ESR <2.6 were re-treated if and when this increased to ≥2.6. Further courses were permitted 24 weeks following each course based on the same criteria.
Concomitant glucocorticoids (≤10 mg/day prednisolone or equivalent) and non-steroidal anti-infl ammatory drugs were permitted with doses kept stable. Intravenous or intramuscular glucocorticoids and additional DMARDs (non-biological or biological) were prohibited.
Radiographs of the hands, wrists and feet were performed at screening (considered baseline), week 24 and week 52, and read at a central reading facility (Synarc Inc, San Francisco, California, USA) by two independent expert radiologists, blinded to treatment and sequence, using the Genant-modifi ed Sharp scoring system (range 0-290). 12 13 The primary end point of the study was the change in total Genant-modifi ed Sharp score (mTSS) from baseline to week 52. Clinical outcomes at week 52 included the proportion of patients achieving ACR responses relating to 20%, 50%, 70% and 90% improvement from baseline, 14 responses defi ned according to the criteria of the European League Against Rheumatism (EULAR) 15 and change in DAS28-ESR. 11 Durability of response was determined by the proportion of patients achieving a major clinical response (MCR; defi ned as maintenance of ACR70 response ≥6 months). Physical function was determined using the Health Assessment Questionnaire-Disability Index (HAQ-DI), including the proportion of patients achieving minimum clinically important differences (MCID; an improvement of ≥0.22). 16 Adverse events were recorded throughout the study and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.
Statistical analysis
Based on simulations using distributions that match the data published from the ASPIRE study, 3 with data analysed using group.bmj.com on May 27, 2013 -Published by ard.bmj.com Downloaded from of erosive damage and higher proportions of patients with no progression of joint damage (defi ned as change in mTSS score ≤0) ( table 2 ) in the rituximab 2×1000 mg + MTX group versus MTX alone.
A reduction in the progression of joint damage in the rituximab 2×1000 mg + MTX arm was evident by 24 weeks, with a markedly slower rate of change from 24 to 52 weeks. During this second 6-month period, both doses of rituximab reduced the progression of joint damage (including erosion and joint space narrowing) versus MTX alone ( fi gure 2A ).
At week 52 both doses of rituximab + MTX were associated with improved clinical outcomes compared with MTX alone across a broad range of end points including signifi cantly higher proportions of patients achieving ACR20, 50, 70 and 90 responses ( table 2 ) . MCRs were achieved in 8%, 18% (p=0.0015) and 21% (p<0.0001) of patients in the MTX alone, rituximab 2×500 mg and rituximab 2×1000 mg groups, respectively.
Greater decreases from baseline in DAS28-ESR were observed in both the rituximab 2×500 mg and 2×1000 mg groups compared with MTX alone from week 8 through to week 52 ( fi gure 2B ), with signifi cant differences from baseline observed at week 52 versus MTX alone (adjusted mean −3.05 and −3.21 vs −2.06; p<0.0001 for both). Within both rituximab groups the incidence of remission (defi ned as DAS28-ESR <2.6) increased throughout the study period and by week 52 was achieved in 13%, 25% and 31% in the MTX alone, rituximab 2×500 mg and rituximab 2×1000 mg groups, respectively (p<0.001 for both rituximab groups; see table 2 and fi gure S2 in online supplement). EULAR good responses were achieved in signifi cantly higher proportions of patients in both rituximab groups versus MTX ( table 2 ) . Improvement in function as determined by mean changes in the HAQ-DI from baseline to week 52 was signifi cantly greater in the rituximab 2×500 mg and 2×1000 mg groups compared with MTX alone (−0.905 and −0.916 vs −0.628, respectively; p<0.0001 for both), with higher proportions of patients achieving an MCID than in the MTX alone group ( table 2 ) .
Effi cacy in subgroups
Subgroup analysis indicated that treatment effects were observed across multiple end points in the majority of subgroups based on baseline characteristics (change in mTSS across subgroups is shown in table S1 in the online supplement). This included patients with high disease activity, elevated infl ammatory markers, and RF-and/or ACPA-seropositive disease. Responses in patients seropositive for RF and/or ACPA were enhanced compared with patients seronegative for both autoantibodies across most end points ( table 2 ) . As with all subgroups with relatively small sample sizes, the data in the seronegative subgroup should be interpreted with caution.
Safety outcomes
Adverse events were reported in 81%, 76% and 79% of patients treated with MTX alone, rituximab 2×500 mg or rituximab 2×1000 mg, respectively, with serious adverse events in 10%, 9% and 10%, respectively ( table 3 ). Adverse events leading to withdrawal included exacerbation of RA (fi ve patients in the MTX alone group) and infusion-related reactions (one patient in the rituximab 2×500 mg group and three patients in the rituximab 2×1000 mg group). There were three deaths (two cases of pneumonia, including a case of Pneumocystis jiroveci pneumonia (PJP) and one cerebral infarct), all of which occurred in the MTX alone group. 90% of treated patients completed up to the week 52 primary end point, with the primary reason for early withdrawal in all groups being lack of therapeutic response ( fi gure 1 ).
Most patients (80-84%, balanced across treatment groups) received a second course of treatment. The majority of second courses (approximately 80%) were administered by week 30. A higher proportion of patients treated with MTX alone received a third course compared with either rituximab group (44% vs 37% and 36%, respectively). The mean dose of MTX was >18 mg/week in all groups by week 8 (median dose 19-20 mg/week).
At the week 52 primary end point analysis, rituximab 2×1000 mg + MTX was associated with a signifi cant reduction in the progression of joint damage compared with MTX alone (mean change in mTSS 0.359 vs 1.079; p=0.0004; table 2 ). The robustness of the primary outcome was supported by numerous sensitivity analyses, including the per-protocol analysis and analyses using various imputation rules for missing data. A cumulative probability plot showing the change from baseline to week 52 in mTSS for the ITT population (fi gure S1 in online supplement) shows that the highest proportion of non-progressors was observed in patients in the rituximab 2×1000 mg group. Patients with larger changes in mTSS, and therefore more rapid progression, were mainly limited to the MTX alone group (see fi gure S1 in online supplement).
Although slower progression of joint damage was also observed with rituximab 2×500 mg + MTX, the difference did not achieve statistical signifi cance compared with MTX alone. An exploratory analysis indicated that rituximab 2×1000 mg + MTX resulted in slower progression of joint damage versus rituximab at the lower dose (p=0.0369). This apparent difference between the rituximab doses was extensively explored and did not appear to be due to small numbers of rapidly progressing patients in the lower dose group; indeed, separation of the doses was observable from the 70th percentile. Multiple robustness analysis also demonstrated signifi cant outcomes only with the higher dose.
Secondary radiographic end points refl ected that of the primary assessment, with signifi cantly reduced progression Figure 1 Patient disposition. *Patients are grouped according to treatment received. Note that seven patients were randomised and not treated; these patients are grouped under their randomised treatment group (two placebo + MTX, three rituximab 2×500 mg + MTX, two rituximab 2×1000 mg + MTX); three patients received incorrect medication for their fi rst treatment course (one placebo + MTX patient received rituximab 2×500 mg; one rituximab 2×500 mg + MTX patient received placebo + MTX; one rituximab 2×1000 mg + MTX patient received placebo + MTX). MTX, methotrexate. 
DISCUSSION
This is the fi rst study of initiating a targeted B cell therapy in MTX-naïve patients with active RA. Over 52 weeks the study showed that, compared with MTX alone, rituximab 2×1000 mg + MTX was signifi cantly more effective in inhibiting the progression of joint damage and in improving clinical outcomes in a population of patients with RA, of whom approximately 90% were seropositive for RF and/or ACPA autoantibodies. Although the lower dose of rituximab (2×500 mg) was associated with improved symptoms, this dose did not meet the primary end point of reducing joint damage.
Both doses of rituximab were highly effective in relieving the signs and symptoms of RA. Importantly, the proportions of patients achieving high-hurdle end points, including those with 90% improvement in their disease symptoms (ACR90) Infusion-related reactions, consisting predominantly of throat irritation, pruritus, rash and fever, were most frequent in patients in the rituximab 2×1000 mg + MTX group; however, this was apparent only for the fi rst infusion of the fi rst course with frequency of infusion-related reactions similar in all groups thereafter ( table 3 ) .
Serious infections were reported more frequently in the MTX alone group (5%) than in either rituximab group (2% and 3% for the 2×500 mg and 2×1000 mg groups, respectively), with rates of serious infections per 100 patient-years' exposure also higher in this group ( table 3 ) . There were two opportunistic infections (both PJP), one in the rituximab 2×500 mg group, which resolved with treatment, and one in the MTX alone group, which was fatal. Progressive multifocal leucoencephalopathy was not observed in this study. is unusual. A defi nitive explanation is unknown; however, one hypothesis may be related to the ability of the rituximab 2×1000 mg dose to induce more complete B cell depletion in non-peripheral compartments. 20 21 In this model, more pronounced depletion of synovial B-lineage cells is required for radiographic relative to clinical outcomes. Thus, the infl uence of B cells may have a different dynamic to the effects that are related to clinical responses. This hypothesis may be supported by studies in monkeys, which have shown greater B cell depletion in lymphoid tissues following repeat treatments. 22 Given that a high proportion of patients in all groups received retreatment in the current study, more complete depletion in the synovium following re-treatment may provide some explanation as to the enhanced effect on joint damage observed in the second half of the study.
This observation also suggests that the labelled dose of rituximab 2×1000 mg remains appropriate since this was the only dose that both improved clinical symptoms and signifi cantly inhibited progression of joint damage. However, whether continued repeat treatment with this dose or the lower dose of 2×500 mg is optimal has not been addressed in this study and is perhaps an area for further investigation.
Importantly, compared with MTX alone, improved clinical and radiographic outcomes were observed with rituximab + MTX in patients with accepted markers of progressive disease (eg, high disease activity or CRP). Consistent with previous as well as those achieving DAS28-ESR remission, were signifi cantly greater with rituximab + MTX compared with MTX alone. Responses were sustained over time, as demonstrated by signifi cantly higher proportions of patients achieving an MCR in both rituximab groups. Functional ability was also improved with signifi cantly greater mean changes in the HAQ-DI in both rituximab treatment groups compared with MTX alone, as well as higher proportions of patients achieving clinically meaningful changes. Given that the HAQ-DI is a major predictor of work disability as well as costs of disease treatment, 17 its signifi cant improvement in this young and functionally impaired patient population is of particular clinical relevance.
Rituximab 2×1000 mg signifi cantly reduced the progression of joint damage within 6 months. Importantly, the degree of inhibition was notably greater from weeks 24 to 52, with a 91% reduction in the progression of joint damage compared with MTX alone. Exploratory analysis also showed signifi cant effects on reducing joint damage in the rituximab 2×500 mg group during this second 6-month period. The slower onset of radiographic inhibition with this dose is in contrast to that observed for clinical outcomes, which were comparable over time for both doses of rituximab ( fi gure 2B ). Disconnects between clinical responses and radiographic outcomes with rituximab and with TNF inhibitors have been reported 18 19 ; however, the fi nding that different doses of the same therapeutic agent have similar clinical effects but differential radiographic outcomes group.bmj.com on May 27, 2013 -Published by ard.bmj.com Downloaded from reports, 23 24 outcomes were enhanced in patients seropositive for RF or ACPA at baseline compared with patients who were seronegative for both.
The safety profi le in this early RA cohort is consistent with that published with rituximab in patients with later stage disease 7 25 with no new or unexpected safety fi ndings observed. The rate of serious infection was low and consistent with rates previously published for rituximab in RA. 26 Two opportunistic infections were reported, both of which were cases of PJP (including one in a patient receiving MTX alone with a fatal outcome). Although the incidence of PJP in patients with RA is thought to be low, cases have been reported with low-dose MTX as well as in patients treated with biological therapies. 27 28 With the exception of the frequency of infusion-related reactions to the fi rst infusion of the fi rst treatment course, the safety profi les between the two rituximab dose groups were comparable.
In summary, this is the fi rst evidence that targeted B cell depletion with rituximab 2×1000 mg + MTX is an effective and well-tolerated therapy for the treatment of MTX-naïve RA. The critical treatment goals of disease remission, inhibition of joint damage and improved functional ability were all signifi cantly improved compared with the standard of care treatment (MTX) in this important patient population.
